The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes. A new report explains why patients with myelodysplastic syndromes (MDS) become ...

Myelodysplastic syndromes (MDS) are blood cancers caused by an insufficient production of healthy blood cells. Production of irregular cells leads to anemia, where the body’s organs and tissues don’t ...

Patients with histories of inflammatory bowel disease and systemic lupus erythematosus were also at elevated risks of myelodysplastic syndromes (MDS), the authors found. A new report shows that ...

Myelodysplastic syndromes (MDSs) are rare blood cancers in which your bone marrow overproduces abnormal, immature blood cells that crowd out healthy red blood cells, white blood cells, or platelets.

Successful Management of Neutropenic Sepsis Is Key to Better Survival of Patients With Blood Cancer in Sri Lanka: Real-World Data From the Resource-Limited Setting Myelodysplastic syndromes (MDS) ...